Immuneoncia Is An Immuno Oncology Centric Biopharmaceutical Companyestablished In 2016 As A Joint Venture Company Between Yuhan And Sorrentoimmuneoncia Will Leverage Both Companiesexpertise In Drug Development And Antibody Engineeringour Mission Is To Bring Safeeffectiveand Novel Immunotherapies To Oncology Patients World Wideimmuneoncia S Portfolio Includes Diverse Immune Checkpoint Antibodiesthe Lead Antibody Imc 001 Phase I Study Was Completed In Feb 2019 And Its Phase 2 Study Is Being Preparedimmuneoncia Is Also Developing Several Antibodies Targeting Novel Immune Checkpoints
